Total Payments
$36,939
2024 Payments
$6,900
Companies
2
Transactions
22
Payment Breakdown by Category
Research$32,170 (87.1%)
Other$3,700 (10.0%)
Travel$1,041 (2.8%)
Food & Beverage$27.50 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $32,170 | 15 | 87.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,700 | 1 | 10.0% |
| Travel and Lodging | $1,041 | 5 | 2.8% |
| Food and Beverage | $27.50 | 1 | 0.1% |
Payments by Type
Research
$32,170
15 transactions
General
$4,769
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $35,898 | 17 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,041 | 5 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,900 | 2 | PFIZER INC. ($6,900) |
| 2023 | $20,600 | 7 | PFIZER INC. ($20,600) |
| 2022 | $8,370 | 7 | PFIZER INC. ($8,370) |
| 2019 | $1,069 | 6 | GlaxoSmithKline, LLC. ($1,041) |
All Payment Transactions
22 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/30/2024 | PFIZER INC. | CIBINQO (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ABROCITINIB CLINICAL PUBLICATION PROGRAM • Category: Inflammation & Immunology | ||||||
| 03/06/2024 | PFIZER INC. | CIBINQO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $3,700.00 | General |
| Category: Inflammation & Immunology | ||||||
| 12/20/2023 | PFIZER INC. | CIBINQO (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ABROCITINIB CLINICAL PUBLICATION PROGRAM • Category: Inflammation & Immunology | ||||||
| 10/26/2023 | PFIZER INC. | CIBINQO (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ABROCITINIB CLINICAL PUBLICATION PROGRAM • Category: Inflammation & Immunology | ||||||
| 10/13/2023 | PFIZER INC. | CIBINQO (Drug) | — | In-kind items and services | $1,400.00 | Research |
| Study: ABROCITINIB CLINICAL PUBLICATION PROGRAM • Category: Inflammation & Immunology | ||||||
| 09/13/2023 | PFIZER INC. | CIBINQO (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ABROCITINIB CLINICAL PUBLICATION PROGRAM • Category: Inflammation & Immunology | ||||||
| 09/01/2023 | PFIZER INC. | CIBINQO (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ABROCITINIB CLINICAL PUBLICATION PROGRAM • Category: Inflammation & Immunology | ||||||
| 07/14/2023 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/26/2023 | PFIZER INC. | CIBINQO (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ABROCITINIB CLINICAL PUBLICATION PROGRAM • Category: Inflammation & Immunology | ||||||
| 11/22/2022 | PFIZER INC. | CIBINQO (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ABROCITINIB CLINICAL PUBLICATION PROGRAM • Category: Inflammation & Immunology | ||||||
| 10/24/2022 | PFIZER INC. | CIBINQO (Drug) | — | In-kind items and services | $620.00 | Research |
| Study: ABROCITINIB CLINICAL PUBLICATION PROGRAM • Category: Inflammation & Immunology | ||||||
| 09/09/2022 | PFIZER INC. | CIBINQO (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: ABROCITINIB CLINICAL PUBLICATION PROGRAM • Category: Inflammation & Immunology | ||||||
| 08/31/2022 | PFIZER INC. | CIBINQO (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: ABROCITINIB CLINICAL PUBLICATION PROGRAM • Category: Inflammation & Immunology | ||||||
| 08/23/2022 | PFIZER INC. | CIBINQO (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: ABROCITINIB CLINICAL PUBLICATION PROGRAM • Category: Inflammation & Immunology | ||||||
| 08/05/2022 | PFIZER INC. | CIBINQO (Drug) | — | In-kind items and services | $1,400.00 | Research |
| Study: ABROCITINIB CLINICAL PUBLICATION PROGRAM • Category: Inflammation & Immunology | ||||||
| 07/01/2022 | PFIZER INC. | CIBINQO (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: ABROCITINIB CLINICAL PUBLICATION PROGRAM • Category: Inflammation & Immunology | ||||||
| 10/01/2019 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $340.00 | General |
| 10/01/2019 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $291.00 | General |
| 10/01/2019 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $195.50 | General |
| 10/01/2019 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $107.30 | General |
| 10/01/2019 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $107.30 | General |
| 06/11/2019 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: DERMATOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $28,970 | 14 |
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
About Dr. Hernan Valdez, MD
Dr. Hernan Valdez, MD is a Infectious Disease healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013094739.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hernan Valdez, MD has received a total of $36,939 in payments from pharmaceutical and medical device companies, with $6,900 received in 2024. These payments were reported across 22 transactions from 2 companies. The most common payment nature is "" ($32,170).
Ad
Practice Information
- Specialty Infectious Disease
- Location Bronx, NY
- Active Since 11/01/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1013094739
Products in Payments
- CIBINQO (Drug) $32,670
- XELJANZ (Drug) $3,200
- EUCRISA (Drug) $27.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Bronx
Dr. Peter Alpert, Md, MD
Infectious Disease — Payments: $293,906
Infectious Disease $293,906
Mr. Norbert Brau, M.d, M.D
Infectious Disease — Payments: $180,229
Infectious Disease $180,229
Barry Zingman, Md, MD
Infectious Disease — Payments: $34,198
Infectious Disease $34,198
Arturo Casadevall, Md, MD
Infectious Disease — Payments: $29,572
Infectious Disease $29,572
Dial Hewlett, Md, MD
Infectious Disease — Payments: $19,196
Infectious Disease $19,196
Julio Quintanilla, M.d, M.D
Infectious Disease — Payments: $16,077
Infectious Disease $16,077